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Abstract
Background: Cationic derivatives of polyprenols (trimethylpolyprenylammonium iodides – PTAI) with variable chain
length between 6 and 15 isoprene units prepared from naturally occurring poly-cis-prenols were tested as DNA
vaccine carriers in chickens and mice. This study aimed to investigate if PTAI could be used as an efficient carrier
of a DNA vaccine.
Methods: Several vaccine mixtures were prepared by combining different proportions of the vaccine plasmid
(carrying cDNA encoding a vaccine antigen, hemagglutinin from H5N1 influenza virus) and various compositions
of PTAI. The vaccines were delivered by intramuscular injection to either chickens or mice. The presence of specific
antibodies in sera collected from the immunized animals was analyzed by enzyme-linked immunosorbent assay (ELISA)
and hemagglutination inhibition (HI) test.
Results: The mixtures of PTAI with helper lipids, such as DOPE (1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine),
DC-cholesterol [{3ß-[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol} hydrochloride] or DOPC (1,2-dioleoyl-sn-
glycero-3-phosphatidylcholine) induced strong humoral response to the antigen encoded by the DNA vaccine plasmid.
Conclusion: The animal immunization results confirmed that PTAI compositions, especially mixtures of PTAI with DOPE
and DC-cholesterol, do work as effective carriers of DNA vaccines, comparable to the commercially available lipid
transfection reagent.
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Background
In the past two decades considerable development of
DNA vaccine technology has been observed. This tech-
nology has emerged as a promising alternative to tra-
ditional vaccines and can be applied for therapy of
human and animal infections, cancers, allergies or auto-
immune disorders. The main advantages of DNA vac-
cines are: (i) rapid and relatively inexpensive mass
production and (ii) simplicity of development, modifi-
cation, formulation and preparation. DNA vaccines can
induce both humoral and cellular responses highly spe-
cific to the chosen antigen, of which the structure and
posttranslational modification are like those in natural
infection. The mechanism by which a DNA vaccine
works has been presented in several recently published
reviews, for example [1–3]. Briefly, a DNA vaccine which
consists of an animal expression vector carrying a se-
quence encoding a selected antigen and DNA carrier is
injected into the tissue, resulting in somatic and/or
antigen-presenting cell (APC) transfection. Then, vac-
cine DNA translocates to the cell nucleus where the
transgene is transcribed by host enzymes followed by
translation in the cytoplasm. After processing, the anti-
genic peptides bind to MHC class I and class II and are
presented by APC to activate naïve T cells. Alternatively,
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secreted antigenic proteins can be processed to activate
B cells for antibody production. In comparison to live at-
tenuated or inactivated vaccines the immunogenicity of
DNA vaccines, especially in humans and large animals,
is usually lower. Improvement of both the expression
level of an antigen and the efficiency of transfection are
essential for elevation of DNA immunization efficacy.
Thus various modifications of expression cassettes (e.g.
codon optimization, introducing of various regulatory
elements, other changes in the antigen coding sequence),
biological and biochemical adjuvants, different carriers
and vaccination routes and other strategies were widely
investigated [4].
One of the commonly used methods of delivery of
DNA vaccines is the application of lipofectants, i.e. cat-
ionic lipids as DNA vehicles, which are able to sponta-
neously interact with negatively charged nucleic acids
forming lipoplexes (lipid–nucleic acid complexes). Non-
specific interactions with the surface of cellular mem-
branes stimulate the uptake of lipoplexes into the cell
via endocytosis, while the presence of helper lipids (e.g.
neutral lipids, such as DOPE [1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine], DC [{3ß-[N-(N′,N′-dimethy
laminoethane)-carbamoyl] cholesterol} hydrochloride] or
DOPC [1,2-dioleoyl-sn-glycero-3-phosphatidylcholine])
modifies the properties of lipoplexes and facilitates DNA
release from endosomes.
A broad prospect for applications of cationic lipids as
DNA vaccine carriers and adjuvants is the basis for ex-
tensive studies aimed at elaboration of effective and safe
lipid vehicles [5, 6]. Numerous studies have confirmed
the positive effect of lipid adjuvants [7, 8]; however, so
far the ultimate lipid component of vaccines remains to
be discovered. This might be the result of a broad diver-
sity of vaccines and their administration protocols, di-
vergent diseases and responsive mechanisms of the
organisms and, finally, numerous side effects caused by
vaccination. An additional level of complexity in the
search for optimal vaccine carriers and adjuvants is added
by the diversity of immunization mechanisms. All these
issues result in a complex relationship between the com-
ponents of the vaccine and their safety and efficacy.
Cationic derivatives of polyprenols, named either PTAI
(trimethylpolyprenylammonium iodides) or AP (amino-
prenols), have been already recognized as lipofectants and
their usage in in vitro cell transfection described [9–11].
In this work we investigated if PTAI with diverse
length polyprenyl chains (6–15 units) can be used as ef-
fective carriers of DNA vaccines. In immunization ex-
periments we used two animal models, chickens and
mice. Animals were immunized with the DNA vaccine
encoding hemagglutinin (HA) from influenza virus
H5N1 which was developed and successfully used by us
previously [12–14]. The immunogenicity of the DNA
vaccine was evaluated by enzyme-linked immunosorbent
assay (ELISA) and hemagglutination inhibition (HI) test.
Comparison of the results obtained with vaccine mix-
tures containing several compositions of PTAI is pre-
sented and discussed.
Methods
Vaccine plasmid
The K3 plasmid is a recombinant expression vector pCI
(Promega) carrying under control of the cytomegalo-
virus promoter the cDNA encoding the full length
hemagglutinin (without cleavage site between subunits
HA1 and HA2) from the highly pathogenic H5N1 influ-
enza virus strain A/swan/Poland/305-135 V08/2006
(clade 2.2.) [12]. After propagation in Escherichia coli
(DH5α strain), plasmid DNA was isolated using the
NucleoBond® PC 10000 EF endotoxin-free giga purifica-
tion kit (Macherey-Nagel) which ensures endotoxins
level < 0.1EU/μg DNA. Purified DNA was dissolved in
PBS buffer, pH 7.4.
Preparation of PTAI compositions
Four types of PTAI preparation with different length
polyprenoid chains were used in this work: (i) PTAI-11
containing 11 isoprenoid subunits, (ii) PTAI-15 contain-
ing 15 isoprenoid subunits, (iii) PTAI-6-8 and (iv) PTAI-
10-14, containing a mixture of polyprenols with chain
lengths from 6 to 8 subunits and from 10 to 14 subunits,
respectively (Fig. 1). The PTAI were obtained as previ-
ously described [10, 11], (patent PL 2012, B1 211824, Pa-
tent Office of the Republic of Poland). PTAI and helper
lipids (DOPE, DC-cholesterol and DOPC were dissolved
in 99.8% ethanol). They were mixed in appropriate ratios
in order to achieve the following molar ratios in the
mixture: The following five compositions containing
PTAI and helper lipids in the indicated molar ratios
were prepared: PTAI-6,7,8 + DOPE – 1,5:1; PTAI-
11 + DOPE + DC-cholesterol – 1:1:1; PTAI-11/DOPE/
DC-cholesterol/DOPC - 1 : 1 :1 : 1, PTAI-15/DOPE/DC-
cholesterol/DOPC - 1 :1 :1 : 1 and PTAI-10-14/DOPE/
DC – 1:1:1. Then the obtained mixtures were mixed
with endotoxin tested DMEM F-12 HAM cell culture
medium without additions of serum and antibiotics and
intensely vortexed for 3 min. Ethanol content in the
Fig. 1 Structure of trimethylpolyprenylammonium iodides (PTAI). PTAI
with diverse length of polyprenoid chains were investigated, respectively
n= 6-8 (mixture), n= 11, n= 15 and n= 10-14 (mixture)
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mixtures was: PTAI-11/DOPE/DC cholesterol/DOPC –
21,3%, PTAI-15/DOPE/DC cholesterol/DOPC – 15,6%,
PTAI-6-8/DOPE – 11,4%, PTAI-11/DOPE/DC-cholesterol
– 20,7%, PTAI-10-14/DOPE/DC-cholesterol – 20,7%. The
compositions were stored at 4 °C up to 5 days.
Preparation of vaccine mixtures and animal vaccination
The vaccine mixtures were prepared by combination of
the K3 plasmid with the prepared PTAI compositions in
different PTAI :DNA ratios (w/w), depending on the
DNA dose used in the experiment which is indicated
separately. Before injections PTAI compositions were
mixed with plasmid DNA and incubated for 30 min at
room temperature. The mixtures of K3 plasmid DNA
(amounts corresponding to the K3 amounts used with
PTAI) and Lipofectin® Transfection Reagent (Invitro-
gen™) served as pertinent controls. These mixtures were
prepared by mixing DNA with this carrier at a ratio
(w:v) of 6 : 1, as described previously [12]. Briefly, Lipo-
fectin was initially diluted in PBS, mixed with DNA and
incubated for at least 10 min at room temperature, ac-
cording to manufacturer protocol.
One vaccine dose for chickens contained either 125 μg
or 62.5 μg of plasmid DNA in a final volume of 160 μl or
100 μl, respectively, while one vaccine dose for mice con-
tained 10 μg of plasmid DNA in a final volume of 50 μl.
Two types of chicken: broilers (Ross 308) and laying
hens (Rosa 1) were immunized intramuscularly in the
breast muscle twice on the 7th and the 21st day of life.
Blood samples were taken from the wing vein 14, 21 and
28 days after initial immunization. Mice (BALB/c) were
immunized intramuscularly twice on the 35th and 49th
day of life. Blood was collected at days 14, 21 and 28 days
after initial immunization. The group sizes (n = 5-10 for
the tested groups and n = 2-5 for the control groups) are
indicated in the respective figures.
Details of the PTAI compositions and vaccine doses
used in the three immunization experiments are indi-
cated in Table 1.
ELISA assay and HI test
The ELISA assay detecting anti-H5 IgY in chicken sera
and anti-H5 IgG in mouse sera as well as HI test were
performed as described previously [12, 13]. Purified re-
combinant H5 HA (A/swan/Poland/305-135 V08/2006)
derived from a baculovirus system (Oxford Expression
Technologies, UK) was used for plates coating in ELISA
assay. Anti-H5 IgY were detected with goat anti-chicken
IgY (Fc-specific)-HRP (Thermo Scientific) while anti-H5
IgG were detected with goat anti-mouse IgG-AP (Sigma-
Aldrich). For one dilution ELISA sera were diluted 1:200
(chickens) or 1:100 (mice). For end-point ELISA sera
were serially diluted and the end-point titer of the anti-
H5 antibodies was determined as the inverse value of
the highest serum dilution at which a result higher than
the estimated value: background + 3SD (three times the
value of the standard deviation) was obtained. HI test
were performed according to the OIE standard proced-
ure using the commercially available antigen from low
pathogenic H5N2 strain, A/chicken/Belgium/150/1999
(DG Deventer, Netherlands) which share 96% protein se-
quence similarity with vaccine antigen. Serially diluted
sera were incubated with antigen for 25 min, and then
incubated with chicken erythrocytes for 30 min. HI titer
was defined as the reciprocal of the highest dilution of
sera that completely inhibited hemagglutination.
A non-parametric Mann–Whitney U test, which is a
component of Statistica 12 software (StatSoft, Poland),
was used to evaluate the statistical differences between
groups. A value of p < 0.05 was considered significant.
Results
Chicken immunization
The groups of chickens, broilers in the first experiment
and laying hens in the second, were immunized with
two doses of the DNA vaccines containing the K3 plas-
mid and different PTAI compositions (Table 1). In the
first experiment four different PTAI compositions: (i)
PTAI-6-8/DOPE, (ii) PTAI-11/DOPE/DC, (iii) PTAI-11/
DOPE/DC/DOPC and (iv) PTAI-15/DOPE/DC/DOPC
mixed with 125 μg of K3 were tested along with the
positive (K3 mixed with Lipofectin® Transfection Re-
agent) and negative (pCI mixed with one of the carriers)
controls. The PTAI :DNA ratios (w/w) in vaccine com-
positions K3-PTAI 6-8/DOPE, K3-PTAI-11/DOPE/DC,
K3-PTAI-11/DOPE/DC/DOPC and K3-PTAI-15/DOPE/
DC/DOPC were 0.9 : 1, 0.8 : 1, 1.3 : 1 and 1.6 :1, respect-
ively, while calculated charge ratios PTAI+:DNA− or
(PTAI + DC)+:DNA− were 1:2.3, 1:1.7, 1:1.1 and 1:1.1,
respectively. Efficacy of the applied vaccines was assayed
by ELISA and HI tests which allowed estimation of the
level of induced specific anti-HA antibodies in the col-
lected sera. Independently of the carrier, most chickens
immunized with K3 developed a specific antibody
against HA, while those vaccinated with the empty vec-
tor (pCI, group 6) clearly showed no anti-H5 response
(Fig. 2a). All groups immunized with K3 showed an evi-
dent increase of humoral response after booster
immunization. However, only in the groups vaccinated
with K3-PTAI-6-8/DOPE (group 1) and K3-PTAI-11/
DOPE/DC (group 2) did 100% of chickens produce spe-
cific anti-H5 antibodies. In the K3-PTAI-11/DOPE/DC/
DOPC (group 3) and K3-PTAI-15/DOPE/DC/DOPC
(group 4) one out of ten and three out of seven immu-
nized chickens, respectively, gave negative results. The
strongest responses to vaccination were observed in the
K3-PTAI-11/DOPE/DC group. This group had not only
the best individual chicken responses in ELISA (Fig. 2a)
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but also was significantly different from all other groups
in the HI test, had the highest scores for individual
chickens, and the highest median and geometric mean
of HI in comparison to the other groups (Fig. 2b).
Based on one-dilution ELISA and HI tests the PTAI-
11/DOPE/DC composition was selected for further trials
in the second experiment. Vaccine doses were prepared
by mixing PTAI-11/DOPE/DC with 125 μg or 62.5 μg of
K3 plasmid DNA (Table 1). Three vaccine compositions
were used: (i) K3-125/PTAI (0.8), consisting of 125 μg of
DNA per vaccine dose and a PTAI-11 :DNA (w/w) ratio
of 0.8 : 1, (ii) K3-62.5/PTAI (1.6), consisting of 62.5 μg of
DNA and a PTAI :DNA (w/w) ratio of 1.6 : 1 and (iii)
K3-62.5/PTAI (0.8), consisting of 62.5 μg of DNA and a
PTAI-11 :DNA (w/w) ratio of 0.8 : 1. Charge ratios calcu-
lated as (PTAI + DC)+:DNA− for these three vaccine
compositions were 1:1.7, 1:0.8, and 1:1.7, respectively.
Simultaneously, vaccine compositions containing Lipo-
fectin® instead of PTAI-11/DOPE/DC (K3-125/L and
K3-62.5/L, containing 125 μg and 62.5 μg DNA, respect-
ively) and vaccine samples without any carrier (K3-125
and K3-62.5) were prepared. As expected, the anti-H5
levels in the groups immunized without any carrier were
lower and much more variable than in the groups im-
munized with the carriers. Therefore no end-point titer
ELISA was performed in the groups immunized without
carrier. Interestingly, the PTAI compositions containing
the lower dose of plasmid DNA (62.5 μg) seemed to be
slightly superior to the vaccine containing the mixture
of the same DNA dose with Lipofectin®, the reference
carrier (Fig. 3a). This observation is partially supported
by statistical analysis, the results of the HI test (Fig. 3b)
and the results of endpoint titer evaluation in individual
sera collected on day 28 post immunization (Fig. 4),
where the highest titers were observed in the K3-62.5/
PTAI(0.8) group (geometric mean 1.3 × 105). Moreover,
the K3-62.5/PTAI groups, regardless of the PTAI :DNA
ratio, had no low responders (chickens with low end-
point titer of anti-HA antibodies in the serum), in con-
trast to the K3-62.5/L group immunized with the
reference carrier.
Mouse immunization
The efficacy of PTAI as a DNA vaccine carrier was also
tested in mice (Table 1). Animals were intramuscularly
vaccinated with two doses of DNA vaccine. One group
had a vaccine consisting of a mixture of K3 (10 μg) and
PTAI composition (PTAI-10-14/DOPE/DC) with a
PTAI :DNA ratio (w/w) of 0.8 : 1 and calculated charge
ratio [(PTAI + DC)+:DNA−] 1:1.7, while the second
group had a vaccine consisting of a mixture of K3
(10 μg) and Lipofectin®. In the negative control K3 was
replaced with empty pCI vector. The ELISA results
using collected sera demonstrated that the tested PTAI
composition is an effective DNA carrier (Fig. 5). How-
ever, in this experiment no significant differences be-
tween the tested PTAI composition and the control lipid
carrier were observed. For example, in both groups the
Table 1 Details of the tested vaccine mixtures
Animal model Group PTAI compositions or Lipofectin Molar ratio PTAI: helper lipids DNA dose Ratioa
Chicken-broilers 1 PTAI-6-8 with DOPE 1.5:1 125 μg 0.9:1
2 PTAI-11 with DOPE/DC 1:1:1 125 μg 0.8:1
3 PTAI-11 with DOPE/DC/DOPC 1:1:1:1 125 μg 1.3:1
4 PTAI-15 with DOPE/DC/DOPC 1:1:1:1 125 μg 1.6:1
5 Lipofectin n.a 125 μg 1:6
6 PTAI-6-8 with DOPE or Lipofectinb 1.5:1 125 μg 0.9:1 or 1:6
Chicken-layers 1 PTAI-11 with DOPE/DC 1:1:1 125 μg 0.8:1
2 PTAI-11 with DOPE/DC 1:1:1 62.5 μg 1.6:1
3 PTAI-11 with DOPE/DC 1:1:1 62.5 μg 0.8:1
4 Lipofectin n.a 125 μg 1:6
5 Lipofectin n.a 62.5 μg 1:6
6 None n.a 125 μg n.a
7 None n.a 62.5 μg n.a
8 Lipofectin n.a 125 μg 1:6
Mice 1 Lipofectin n.a 10 μg 1:6
2 PTAI-10-14 with DOPE/DC 1:1:1 10 μg 0.8:1
3 PTAI-10-14 with DOPE/DC 1:1:1 10 μg 0.8:1
Vaccine mixtures were prepared by mixing the K3 plasmid with PTAI compositions or Lipofectin. Groups 6 and 7 (chicken-layers) were immunized with vaccine
containing the K3 plasmid in PBS, pH 7.4 without any carriers. aratio for PTAI:DNA (w:w) or for Lipofectin:DNA (v:w) in vaccine doses is indicated; bin control group
empty pCI vector was used with PTAI-6-8 (n = 3) or Lipofectin (n = 2); n.a not applicable
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highest levels of anti-HA specific antibodies were ob-
served 1 week after the booster and in both groups low
responders were present.
Discussion
The promising potential of DNA vaccines stimulates the
search for efficient, safe and cost-effective carriers of nu-
cleic acids suitable for in vivo application. Such carriers
should fulfill several additional criteria. First of all, they
should enhance or facilitate the transfection process dur-
ing vaccination that may translate to higher antigen ex-
pression and immunological response. Secondly, they
also should form DNA complexes that encapsulate and
protect the DNA vaccines. Their ability to act as
adjuvants is also favored. For example, the cationic lipid
formulation Vaxfectin® (Vical Inc.) has been shown to
effectively enhance immune response after DNA vaccin-
ation, not due to increased gene transfer efficiency, but
rather by direct modulation of immune pathways [15, 16].
This adjuvant which is a mixture of a cationic lipid (GAP-
DMORIE) and a neutral phospholipid (DPyPE) was also
tested with protein and inactivated vaccines with promi-
sing results.
Recently, PTAI were demonstrated by us to allow
effective transfection of plasmid DNA complexes into
cells [10, 11]. The aim of this study was evaluation of
PTAI as an efficient carrier of DNA vaccines. Several ex-
perimental DNA vaccines consisting of K3 plasmid and
Fig. 2 Humoral response of broilers to vaccination. Birds were immunized with a mixture of K3 DNA (125 μg) with the PTAI composition as
indicated (PTAI-6-8/DOPE, PTAI-11/DOPE/DC, PTAI-11/DOPE/DC/DOPC, PTAI-15/DOPE/DC/DOPC) or with Lipofectin (L); pCI – group vaccinated
with empty pCI vector with PTAI or Lipofectin. a ELISA results for individual chickens; raw data (◊), median (—) and the 10th and 90th percentiles
(□) are shown for each group; blood collected at indicated day post initial immunization, sera diluted 200-fold. (*) group showed significantly higher
ELISA values than K3-PTAI-11/DOPE/DC/DOPC. (**) group showed significantly higher ELISA values than K3-PTAI-11/DOPE/DC/DOPC and K3-PTAI-15/
DOPE/DC/DOPC (p < 0.05). b HI titers in sera of individual chickens on day 28 post immunization. Geometric means for each group are indicated at
the top of the graph. (***) The K3-PTAI-11/DOPE/DC group showed a significantly higher HI titer than all other groups (p < 0.05)
Stachyra et al. Virology Journal  (2017) 14:168 Page 5 of 9
PTAI compositions with different PTAI :DNA ratios
were studied in two animal models, chickens (broiler
and layer) and mice. As a reference vaccine we used a
mixture of the vaccine plasmid with the transfection
reagent Lipofectin®, which is a 1 : 1 (w/v) liposome for-
mulation of the cationic lipid DOTMA (N-[1-(2,3-dio-
leyloxy) propyl]-n,n,n-trimethylammonium chloride) and
DOPE. Previously, such a vaccine composition has been
shown by us to be highly immunogenic and a dose of
125 μg of DNA protected chickens against challenge
with homologous and heterologous H5N1 virus [12].
In the first animal experiment we used mixtures con-
taining a high concentration of DNA (125 μg/dose) and
variants of PTAI with various length polyprenyl chains
mixed with various combinations of helper lipids: DOPE,
DOPE/DC or DOPE/DC/DOPC. All compositions gave
Fig. 3 Comparison of humoral response of layers after immunization with different K3 vaccine mixtures. Vaccine doses composed of K3 plasmid
alone (125 μg or 62.5 μg) or K3 plasmid with carrier PTAI-11/DOPE/DC (denoted as PTAI) or Lipofectin (L) in different w/w ratios indicated in brackets;
pCI-125 – group vaccinated with empty pCI vector with Lipofectin. a ELISA results for individual chickens; raw data (◊), median (—) and the 10th and
90th percentiles (□) are shown for each group; blood collected at indicated day post initial immunization, sera diluted 200-fold. (*) group showed
significantly higher ELISA values than K3-62.5. (**) group showed significantly higher ELISA values than K3-62.5 and K3-62.5/L (p < 0.05). b HI titers in
sera of individual chickens on day 28 post immunization. Geometric means for each group are indicated at the top of the graph. (*) The K3-62.5/PTAI
(0.8) group showed a significantly higher HI titer than K3-62.5 (p < 0.05)
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positive results in ELISA and HI tests; however, a high
variability of humoral response was apparent in the K3-
125/PTAI-11/DOPE/DC/DOPC and K3-125/PTAI-15/
DOPE/DC/DOPC groups, resulting in significantly lower
antibody levels than other formulations. Interestingly, in
both cases we observed a slow process of precipitation
in the vaccine mixture after blending the vaccine plas-
mid with the PTAI composition, which might be respon-
sible for the observed variability of the individual
immune responses. The highest HI titers (as well as the
highest median and geometric mean of the HI titer)
were in the K3-125/PTAI-11/DOPE/DC group (Fig. 2a
and b). Therefore, this PTAI composition was further
examined using the lower dose of the plasmid (62.5 μg)
in two DNA:PTAI ratios and compared with control
carrier and no carrier. The PTAI composition consisting
of a PTAI :DNA (w/w) ratio of 0.8 : 1 seemed to be more
effective in stimulating specific anti-HA antibodies than
the controls. Presumably, it was more effective than the
control lipid in provoking endocytosis and further DNA
release, which might lead to higher production of the
target antigen. It is also worth mentioning that we
observed some differences between the two chicken
experiments, revealing some inconsistencies in the gen-
eral effectiveness of immunizations in both the PTAI
and Lipofectin groups. A possible explanation may be
the different chicken lines used (with different genotype
and phenotype) and relatively small number of indivi-
duals in groups.
Additionally, we decided to use a similar vaccine com-
position K3/PTAI-10-14/DOPE/DC in mice experi-
ments. From a potential commercial perspective, the
administration of a mixture of polyprenols with different
length chains instead of a single polyprenol (with a de-
fined length polyprenol chain) is economically attractive.
A mixture is easier to obtain due to the lack of a chro-
matographic separation step after plant material isola-
tion. Thus, the PTAI-10-14 mix could be a simpler and
cheaper replacement for the highly effective PTAI-11
lipid. Previously, for the same reasons, the PTAI-6-8
mixture was chosen to be tested in the first chicken ex-
periment. The experiment with mice confirmed that the
Fig. 4 End-point titers of anti-H5 HA antibody in sera collected on the 28th day post immunization. The titer of anti-H5 antibodies was determined as
the inverse value of the highest serum dilution at which a result higher than the estimated value: background + 3SD (three times the value of the
standard deviation) was obtained. If there was no need for dilutions higher than the standard 200-fold dilution (readout < 1 for the 200-fold dilution),
the levels were determined by multiplying the OD value read out in the ELISA test by 200, namely by the inverse value of the serum dilution used in
the ELISA test. Geometric means for each group are indicated at the top of the graph. (*) The K3-62.5/PTAI (0.8) group showed a significantly higher
anti-HA titer than K3-62.5/L (p < 0.05)
Fig. 5 Humoral response of mice after immunization. Vaccine was composed of K3 and one of carrier PTAI-10-14-DOPE/DC-cholesterol or Lipofectin.
Raw data (◊), median (—) and the 10th and 90th percentiles (□) are shown for each group; Blood was collected at the indicated day post initial
immunization, sera diluted 100-fold; pCI – group vaccinated with empty pCI vector with PTAI
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PTAI-10-14 mixture could be used as an efficient DNA
carrier for DNA vaccination purposes.
Efficient delivery of plasmid DNA into host cells is a
challenge of great importance for the development of
DNA vaccines. Early DNA studies in large animal
models and the first human trials resulted in little induc-
tion of immune response in comparison to mouse
models. A possible explanation may be differences in the
DNA uptake of target cells [17]. Intramuscular injection,
which is the most widely used way of DNA immunization
is very susceptible to inter-individual variation related to
differences in cell transfection level at the injection site, as
most of the intramuscularly-injected bare DNA does not
actually transfect cells and is phagocytosed [18]. This
lowers general vaccine efficacy in the population and dis-
rupts the results of clinical trials. Improvements in ef-
ficient and less accidental DNA transfer which results in
high and more equal expression in cells make DNA vac-
cines more effective. Besides mechanical devices and phys-
ical stimulus, various chemical or biomaterial carriers (like
the cationic lipids used in this work) are widely investi-
gated and represent the most promising strategy for DNA
vaccination [19].
Conclusion
In this work, cationic derivatives of polyprenols (PTAI)
were tested in vivo as carriers of DNA vaccines. Several
variants of formulations containing a mixture of differ-
ent PTAI with helper lipids were able to induce high im-
mune responses against the target antigen in chickens
and mice. Such carriers, which can be obtained from
common plant material, are a promising approach for
DNA vaccine optimization, especially given that there is
a great need for systems that make use of natural mate-
rials and processing conditions.
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